Stem Cells Flashcards

1
Q

Totipotent

A

Can become any cell in body or placenta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pluripotent

A

Can become any cell in body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Multipotent:

A

Can become any cell within a specific germ layer or cell lineage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Steps of cell fate

A

Fertilised egg > totipotent stem cell > FATE decision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Embryonic stem cells

A
  • Pluripotent
  • From embryonic tissues
  • Not committed to a specific fate
  • Self-renewing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Adult Stem Cells

A
  • Multipotent
  • From adult tissues
  • Limited resource/difficult access
  • Limited renewal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Induced Pluripotent Stem Cells

A
  • Pluripotent
  • From adult peripheral tissue
  • Genetically manipulated e.g fibroblast
  • Self-renewing, but not for indefinite time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Original protocol

A
  • Retroviral transduction
  • Introducing pluripotent TFs
  • Major rearrangement of epigenome
  • Differentiation into cell type
  • Clear fibroblast for hard wired info
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What processes are requires for cells do go from fibroblast to neurons and glia ??

A

+ Transcription factors or miRNAs

SDR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What processes are required to go from fibroblast to iPSCS?/

A

Fribroblasts > + transient pluripotency factors expression ( epigenetic actviation)
> unstable intermediates > continued expression of pluripotency factors > iPSCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Unstable intermediates

A

Unstable intermediates - 2 pathways
PDR> + neuralising condition to a neural progenitor
OR
Continued expression of pluripotency factors > iPSCs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cheaper and faster alternatives

A

Fibroblast straight to neurons and glia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

IPSCs

A

Large quantities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fibroblast to Neuron

A

one shot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

iPSC reprogramming

A

Rejuventation

old and young fibroblasts to iPSCc motor neuron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Direct Reprogramming

A

Ageing maintenance

YOung and old fibroblast&raquo_space; young Fib-iMN and Old Fib -iMN

17
Q

IPSC-

A

wiped out epigenome
Mimic embryonic stage > result sc are embryonic like
Issue when studying neurodegeneration> often in older population

18
Q

What is the key difference between direct and iPSPC reprogramming ?

A

Direct allows preservation of some of the ageing features

19
Q

Potential for Stem cells

A

• Exploring disease mechanisms
– Study how basic cellular mechanisms are disrupted in disease
• Drug discovery
– High-throughput assays will identify targets. For example, using hSC cell-derived neural cells for an assay to screen drugs for Alzheimer’s disease
• Toxicology testing
- Identify environmental toxins

20
Q

ALS

A

ALS is one of the most common adult onset motor disorders, characterised by progressive degeneration of upper and lower MNs

21
Q

ALS mutations response for 60%of familial cases

A

SOD1, TARDBP, FUS and C9ORF72

22
Q

Difference between clinical ALS and Familial ?

A

clinically undistinguishable

- no in vitro model only a cellular model

23
Q

Astrocytes

A

Astrocytes- support MN metabolic processes and GFs

- neural support cell

24
Q

Drug discovery protocol in ALS patients -

A
  1. skin biopsy of ALs patient
    2 - Donor fibroblast culture
  2. iNPCs - cellular programming with reprogramming genes
  3. Neural cell aggregates
  4. MN and astrocytes in culture
  5. Robotic drug screening - test one chemical compound per well ** identify therapeutic compounds and disease mechanisms**
25
MS Demyelinating disorder - Drug discovery
Oligodendrocyte precursor cells in a well with test compunds - pre myelinatiing oligodendrocyte - fix and anti MBP immunostain - automated image acquisition and quantification *** - treated with 727 drugs stained for myelin looked for compounds promoting myelin - 34
26
Drug screening in AD
- made patient cortical Neurons - ipsc - based trial for mutiple individuals - 1. iPscs 2. patient cortical neurons 3. pharmaceutical compound library 4. chemical structure- based clustering and combination analysis 5. Anti-ab cocktail
27
Stem cell transplants in AD patients
* Provide injured area with trophic factors * Induce activation and proliferation of endogenous neural stem cells * Partial cell replacement